Project TitleIntravenous Formulation of GMC1 for Cancer Treatment
Track Code2016-023
Short Description

The University of Texas at El Paso seeks a partner for licensing a novel compound for the treatment of metastatic prostate cancer and other cancers and diseases that involve androgen, glucocorticoid and progesterone receptors.


The soluble formulation of GMC1 is suitable for intravenous and likely oral administration. GMC1 is a first in class drug for directly targeting the FKBP52 co-chaperone for the treatment of any condition that relies upon a functional androgen, progesterone or glucocorticoid signaling pathway.

Tagsandrogen receptor, cancer, disease, glucocorticoid receptor, inhibition, Intravenous, metastasis, pharmaceutical, progesterone receptor, prostate cancer, treatment, tumor
Posted DateNov 10, 2016 1:37 PM


Marc Cox
Huan Xie
Oscar Ekpenyong


Melissa Silverstein


  • Treats drug resistant metastatic cancer
  • Strong drug safety profile
  • Stable intravenous formulation 
  • Optimal water soluble co-solvent ratios
  • Analysis method will enable further pre-clinical and clinical studies of GMC1

Potential Applications

  • Prostate cancer
  • Breast cancer 
  • Benign prostatic hyperplasia
  • Contraceptives 
  • Androgen receptor related disorders
  • Glucocorticoid receptor related disorders
  • Progesterone receptor related disorders

Contact Information

For more information, please contact UTEP's Office of Technology Commercialization at or 915-747-8030


File Name Description
2016-023 One Pager None Download

Intellectual Property

Patent Number Issue Date Type Country of Filing
62/314,579 None Provisional United States